Nobel Prize to Baruch Blumberg for the discovery of the aetiology of hepatitis B

@article{Zetterstrm2008NobelPT,
  title={Nobel Prize to Baruch Blumberg for the discovery of the aetiology of hepatitis B},
  author={Rolf H Zetterstr{\"o}m},
  journal={Acta P{\ae}diatrica},
  year={2008},
  volume={97}
}
INTRODUCTION The Nobel Prize in Physiology or Medicine for 1976 was jointly awarded to Baruch Blumberg (Fig. 1), Philadelphia, USA and D. Carleton Gajdusek, National Institutes of Health (NIH), Bethesda, USA for ‘their discoveries concerning new mechanisms for the origin and dissemination of infectious diseases’. Blumberg and his group had presented evidence that hepatitis B is caused by a virus, which may be transferred by close contact, via blood, across the placenta from mother to foetus… 
3 Citations

Polyarteritis nodosa: an evolving primary systemic vasculitis.

DADA2 is a genetic cause of medium vessel vasculitis that is important to distinguish from primary PAN as treatment with TNF inhibitors can prevent morbidity and mortality in those with a vasculopathy phenotype.

Animal Models in Pharmacology: A Brief History Awarding the Nobel Prizes for Physiology or Medicine

The use of animal models in NPPM awarded projects, namely in Pharmacology, illustrates their importance, need and benefit to improve scientific knowledge and create solutions.

Statistical Models of Treatment Effects in Chronic Hepatitis B and C

This thesis regards treatment effects in patients with chronic hepatitis B and C, and focuses on the tools that are used to analyse these effects and the state of art of statistical models to study these effects.

References

SHOWING 1-10 OF 29 REFERENCES

Australia antigen and the biology of hepatitis B.

The discovery of the infectious agent associated with hepatitis B and the elucidation of new mechanisms for its dissemination are the consequences of a series of studies involving many investigators

Observations on Australia Antigen in Japanese

In this article, we described anassociation betweenthe presence in serum of Australia and elevated serum glutamate pyruvate transaminase (SGPT) in blood donors, high incidences of Australia antigen

The relation of infection with the hepatitis B agent to primary hepatic carcinoma.

Strategies are discussed which might be effective in preventing the development of carriers with a consequent decrease in the frequency of HBV carriers, chronic hepatitis, and primary hepatic carcinoma.

An antigen detected in the blood during the incubation period of serum hepatitis.

  • A. Prince
  • Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 1968
An antigen that reacted in the immunodiffusion test with serum from multiply transfused patients was detected in the blood during the incubation period prior to the onset of major chemical or clinical abnormalities, suggesting this antigen is specific for serum hepatitis virus.

Study design for a hepatitis B vaccine trial.

A short-time trial of small sample size for an evaluation of the hepatitis B vaccine is proposed and designed if, in preliminary studies, it is shown that the vaccine produces antibody in the patients and that protection against hepatitis B virus would be beneficial to the patients.

Australia Antigen, Transfusion and Hepatitis

The need to develop more sensitive techniques than double diffusion in agar for detecting the antigen and to investigate other agents than the Au(1) antigen is discussed in order to establish a screening procedure of carriers of hepatitis virus.

Global Epidemiology of Hepatitis B Virus

HBV vaccination programs will decrease the future global burden of HBV infection and evidence of reduced burden is mounting in country-specific populations, but vaccination programs have still not been implemented in all countries, thereby maintaining reservoirs of infection and continued HBV transmission.

Hepatitis B virus infection: epidemiology and vaccination.

Making progress towards the elimination of HBV transmission will require sustainable vaccination programs with improved vaccination coverage, practical methods of measuring the impact of vaccination programs, and targeted vaccination efforts for communities at high risk of infection.